https://doi.org/10.4081/reumatismo.2022.1481
The prevalence and clinical spectrum of post-Covid syndrome in patients with rheumatic diseases: a single-center experience
Accepted: 16 March 2022
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Post-coronavirus disease (COVID) syndrome (PCS) is a term used to describe the clinical condition of patients who have recovered from COVID-19 but are still experiencing prolonged effects of infection or persistent symptoms for longer than expected. Although PCS has been previously studied in the general population, it has not been investigated in a specific population of patients with inflammatory rheumatic disease (IRD). This study aims to evaluate the presence and frequency of PCS among our rheumatology outpatients. This is a cross-sectional study of patients with IRD whose symptoms persisted for 12 weeks after the detection of COVID-19 infection. The patients were assessed with a survey form during their routine clinic follow-up or by contacting them by phone. Patients’ demographics, diagnosis, medication, comorbidities, outcome of COVID-19, and symptoms related to PCS were collected. Fifty-three patients with IRD and COVID (mean age: 48.5 13.99 years, 71.7% women) were included. PCS was observed in 36 (67.9%) patients. Twenty-two (41.5%) of them had three or more symptoms; 14 (26.4%) had one or two symptoms. Although more than 30 symptoms were detected, the most frequent were fatigue and weakness. No significant relationship was detected between the development of PCS and gender, age, disease duration, presence of COVID-related complications, and the need for oxygen support, except for smoking which showed a protective effect (p=0.008). PCS was detected in more than half of the patients. There was no independent risk factor for the development of PCS, except smoking.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- C. Montecucco, Outcome predictors in rheumatoid arthritis , Reumatismo: Vol. 56 No. s1 (2004)
- G. Fornaciari, V. Giuffra, Rheumatic diseases at the court of the Medici of Florence: the so-called “gout” of the Medici , Reumatismo: Vol. 61 No. 3 (2009)
- F. Paparo, L.M. Sconfienza, A. Muda, A. Denegri, R. Piccazzo, E. Aleo, M.A. Cimmino, Multimodality imaging of chronic tophaceous gout , Reumatismo: Vol. 62 No. 4 (2010)
- P. Marson, R. Rondinone, M. Vicarioto, Malar rash in a painting by Jean-Baptiste Siméon Chardin (1699-1779) , Reumatismo: Vol. 53 No. 2 (2001)
- F. Oliviero, R. Ramonda, III Course on synovial fluid analysis organized by the Italian Society of Rheumatology , Reumatismo: Vol. 56 No. 3 (2004)
You may also start an advanced similarity search for this article.
